Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer (original) (raw)

• Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9: 753–768
  Article CAS PubMed Google Scholar
• Pollak MN et al. (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505–518
  Article CAS PubMed Google Scholar
• Fuhrer D et al. (2005) Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur J Endocrinol 152: 785–790
  Article CAS PubMed Google Scholar
• Kooijman R et al. (1995) Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med 182: 593–597
  Article CAS PubMed Google Scholar
• Soon L et al. (1999) Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 19: 3816–3828
  Article CAS PubMed PubMed Central Google Scholar
• Hernandez-Sanchez C et al. (1995) The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem 270: 29176–29181
  Article CAS PubMed Google Scholar
• Kim B et al. (1998) Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling. J Biol Chem 273: 34543–34550
  Article CAS PubMed Google Scholar
• Beitner-Johnson D and LeRoith D (1995) Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem 270: 5187–5190
  Article CAS PubMed Google Scholar
• D'Ambrosio C et al. (1996) The role of Grb2 in the growth and transformation of mouse embryo cells. Oncogene 12: 371–378
  CAS PubMed Google Scholar
• Butler AA et al. (1997) In vivo regulation of Crk II and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I: differential effects on tyrosine phosphorylation and association with paxillin. J Biol Chem 272: 27660–27664
  Article CAS PubMed Google Scholar
• Shaw RJ and Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424–430
  Article CAS PubMed Google Scholar
• Wullschleger S et al. (2006) TOR signaling in growth and metabolism. Cell 124: 471–484
  Article CAS PubMed Google Scholar
• Xie Y et al. (1999) Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59: 3588–3591
  CAS PubMed Google Scholar
• Ouban A et al. (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803–808
  Article CAS PubMed Google Scholar
• Khandwala HM et al. (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215–244
  Article CAS PubMed Google Scholar
• Baserga R et al. (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107: 873–877
  Article CAS PubMed Google Scholar
• Yakar S et al. (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16: 407–420
  Article CAS PubMed Google Scholar
• Chan JM et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566
  Article CAS PubMed Google Scholar
• Chan JM et al. (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099–1106
  Article CAS PubMed Google Scholar
• Habuchi T (2006) Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol 2: 233–245
  Article CAS PubMed Google Scholar
• Tsuchiya N et al. (2005) CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 26: 225–231
  CAS PubMed Google Scholar
• Tsuchiya N et al. (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24: 1982–1989
  Article CAS PubMed Google Scholar
• Cheng I et al. (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98: 123–134
  Article CAS PubMed Google Scholar
• Slomiany MG et al. (2006) IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 342: 851–858
  Article CAS PubMed Google Scholar
• Slomiany MG and Rosenzweig SA (2006) Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318: 666–675
  Article CAS PubMed Google Scholar
• Li J et al. (2005) Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 24: 5510–5520
  Article CAS PubMed Google Scholar
• Tang Y et al. (2003) Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63: 1166–1171
  CAS PubMed Google Scholar
• Stearns M et al. (2005) Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 65: 2085–2088
  Article CAS PubMed Google Scholar
• Burroughs KD et al. (2003) Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol Cancer Res 1: 312–322
  CAS PubMed Google Scholar
• Ueda S et al. (2006) Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 19: 788–796
  Article CAS PubMed Google Scholar
• Cunningham MP et al. (2006) Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28: 329–335
  PubMed Google Scholar
• Dunn SE et al. (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58: 3353–3361
  CAS PubMed Google Scholar
• Hofmann F and Garcia-Echeverria C (2005) Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10: 1041–1047
  Article CAS PubMed Google Scholar
• Ullrich A et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo J 5: 2503–2512
  Article CAS PubMed PubMed Central Google Scholar
• Favelyukis S et al. (2001) Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8: 1058–1063
  Article CAS PubMed Google Scholar
• Lou M et al. (2006) The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci USA 103: 12429–12434
  Article CAS PubMed PubMed Central Google Scholar
• Maloney EK et al. (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63: 5073–5083
  CAS PubMed Google Scholar
• Sachdev D et al. (2006) Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66: 2391–2402
  Article CAS PubMed Google Scholar
• Bladt F et al. (2006) Pre-clinical evaluation of the anti-tumor activity of the IGF1R-specific antibody AVE1642 [abstract]. 2006 AACR annual meeting
• Tonra JR et al. (2005) Synergistic anti-tumor effects of anti-EGFR monoclonal antibody Erbitux(R) combined with antibodies targeting IGF1R or VEGFR-2 [abstract]. 2005 AACR annual meeting
• Burtrum D et al. (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912–8921
  CAS PubMed Google Scholar
• Mitsiades CS et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221–230
  Article CAS PubMed Google Scholar
• Garcia-Echeverria C et al. (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231–239
  Article CAS PubMed Google Scholar
• Vasilcanu D et al. (2004) The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor: link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23: 7854–7862
  Article CAS PubMed Google Scholar
• Girnita A et al. (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236–242
  Article CAS PubMed Google Scholar
• Stromberg T et al. (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669–678
  Article PubMed CAS Google Scholar
• Girnita A et al. (2006) The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 12: 1383–1391
  Article CAS PubMed Google Scholar
• Haluska P et al. (2006) In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66: 362–371
  Article CAS PubMed Google Scholar
• Goetsch L et al. (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316–328
  Article CAS PubMed Google Scholar
• Cohen BD et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063–2073
  Article CAS PubMed Google Scholar
• Dunn SE et al. (1997) Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57: 2687–2693
  CAS PubMed Google Scholar
• Macaulay VM et al. (2001) Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20: 4029–4040
  Article CAS PubMed Google Scholar
• Peretz S et al. (2001) ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA 98: 1676–1681
  Article CAS PubMed PubMed Central Google Scholar
• Shahrabani-Gargir L et al. (2004) Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 145: 5679–5687
  Article CAS PubMed Google Scholar
• Turner BC et al. (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079–3083
  CAS PubMed Google Scholar
• Min Y et al. (2005) Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54: 591–600
  Article CAS PubMed PubMed Central Google Scholar
• Wen B et al. (2001) Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85: 2017–2021
  Article CAS PubMed PubMed Central Google Scholar
• Perer ES et al. (2000) Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94: 1–5
  Article CAS PubMed Google Scholar
• Cosaceanu D et al. (2005) Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 222: 173–181
  Article CAS PubMed Google Scholar
• Deutsch E et al. (2004) Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 91: 1735–1741
  Article CAS PubMed PubMed Central Google Scholar
• She QB et al. (2003) Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′kinase/Akt pathway signaling. Clin Cancer Res 9: 4340–4346
  CAS PubMed Google Scholar
• Engelman JA et al. (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788–3793
  Article CAS PubMed PubMed Central Google Scholar
• Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500
  Article CAS PubMed Google Scholar
• Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311
  Article CAS PubMed PubMed Central Google Scholar
• Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139
  Article CAS PubMed Google Scholar
• Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024
  Article CAS PubMed Google Scholar
• Chakravarti A et al. (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200–207
  CAS PubMed Google Scholar
• Jones HE et al. (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793–814
  Article CAS PubMed Google Scholar
• Kobayashi S et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792
  Article CAS PubMed Google Scholar
• Kobayashi S et al. (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096–7101
  Article CAS PubMed Google Scholar
• Camirand A et al. (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7: R570–R579
  Article PubMed PubMed Central CAS Google Scholar
• Lu D et al. (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856–2865
  Article CAS PubMed Google Scholar
• Lu D et al. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280: 19665–19672
  Article CAS PubMed Google Scholar
• Lu Y et al. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857
  Article CAS PubMed Google Scholar
• Albanell J and Baselga J (2001) Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830–1832
  Article CAS PubMed Google Scholar
• Lu Y et al. (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334–341
  Article CAS PubMed Google Scholar
• Camirand A et al. (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521–BR526
  CAS PubMed Google Scholar
• Nahta R et al. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118–11128
  Article CAS PubMed Google Scholar
• Digiovanna, MP and Chakraborty A (2006) Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: dramatic effects of HER2 inhibitors on non-overexpressing cells [abstract]. 2006 AACR annual meeting
• Mitsiades CS and Mitsiades N (2005) Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 5: 487–499
  Article CAS PubMed Google Scholar
• Menu E et al. (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655–660
  Article CAS PubMed Google Scholar
• Martins AS et al. (2006) Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 12: 3532–3540
  Article CAS PubMed Google Scholar
• Haruta T et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783–794
  Article CAS PubMed Google Scholar
• Shi Y et al. (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4: 1533–1540
  Article CAS PubMed Google Scholar
• O'Reilly KE et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508
  Article CAS PubMed PubMed Central Google Scholar
• LeRoith D and Helman L (2004) The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 5: 201–202
  Article CAS PubMed Google Scholar
• Shimizu C et al. (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35: 1537–1542
  Article CAS PubMed Google Scholar
• Yu H et al. (2001) Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 70: 117–122
  Article CAS PubMed Google Scholar
• Wagner K et al. (2005) Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92: 133–140
  Article CAS PubMed Google Scholar
• dos Santos Silva I et al. (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15: 449–455
  Article CAS PubMed Google Scholar
• Guo YS et al. (1995) Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. J Am Coll Surg 181: 145–154
  CAS PubMed Google Scholar
• Morimoto LM et al. (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1204–1211
  Article CAS PubMed Google Scholar
• Zecevic M et al. (2006) IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 98: 139–143
  Article CAS PubMed Google Scholar
• Moon JW et al. (2006) Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 118: 353–356
  Article CAS PubMed Google Scholar
• Jiang Y et al. (2004) A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 21: 755–764
  Article CAS PubMed Google Scholar
• Savage SA et al. (2005) Polymorphisms in genes of the insulin-like growth factor family are associated with osteogenic sarcoma [abstract]. 2005 AACR annual meeting
• Abe S et al. (2006) Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209: 217–228
  Article CAS PubMed Google Scholar
• Fottner C et al. (2006) Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas. J Mol Endocrinol 36: 279–287
  Article CAS PubMed Google Scholar
• Hopfner M et al. (2006) The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135–149
  Article PubMed CAS Google Scholar
• Warshamana-Greene GS et al. (2005) The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11: 1563–1571
  Article CAS PubMed Google Scholar
• Scotlandi K et al. (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65: 3868–3876
  Article CAS PubMed Google Scholar
• Wittman M et al. (2005) Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 48: 5639–5643
  Article CAS PubMed Google Scholar